Abstract
A multicenter study was carried out in patients with RA as a part of the prospective evaluation for safety and efficacy of CCA. A total of 122 patients received CCA for a mean duration of 5.5 months. 69 patients (61.6%) showed better than moderate improvement in the overall improvement evaluation (in evaluated 112 patients) . A statistically significant improvements were noted in the number of painful and swollen joints, joint count, morning stiffness, Lansbury's index and serum IgG. Major adverse reactions were gastrointestinal upset, renal impairment and skin rash. The clinical improvement followed the normalization of peripheral blood lymphocyte count, CD3 and CD4 cells.
Our data confirms that immunomodulating drug CCA is a useful agent in the treatment of patients with RA.
